https://scholars.lib.ntu.edu.tw/handle/123456789/543511
標題: | A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan | 作者: | Chen J.-S. Chao Y. Hsieh R.-K. ANN-LII CHENG Chen P.-M. Chiou T.-J. Chao T.-Y. KUN-HUEI YEH Chen L.-T. Whang-Peng J. |
公開日期: | 2011 | 卷: | 67 | 期: | 6 | 起(迄)頁: | 1281-1289 | 來源出版物: | Cancer Chemotherapy and Pharmacology | 摘要: | Purpose: To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4- dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. Methods: Patients with chemo-na?ve, histologically confirmed AGC were eligible. S-1 was given orally at dose of 40, 50 or 60 mg, twice daily for patients with body surface <1.25, 1.25-1.5 and >1.5 m 2, respectively, on day 1-28 every 42 days/cycle. Results: Thirty-four patients were included. On intent-to-treat analysis, the overall response rate, median progression-free and overall survival were 35.3% [95% confidence interval (CI): 19.2-51.3%], 2.9 (95% CI: 2.4-5.8) months and 9.8 (95% CI: 6.1-NA) months, respectively. The most common grade 3-4 toxicities were anemia 23.5% and neutropenia 11.8%. There were two treatment-related mortality, which occurred in patients with suboptimal renal function underestimated by serum creatinine level at study entry. Single-dose pharmacokinetic study showed trend toward lower AUC5-FU, and higher AUCFT and AUC Oxo comparing to most Western reports. Conclusions: The efficacy, toxicity and pharmacokinetic profiles of S-1 in current study are compatible with those from other Asian populations. Accurate renal function assessment and more closely monitoring is mandatory for S-1 therapy in patients with low body mass. Literature review suggests that, besides AUC5-FU, AUC Oxo may also attribute to the difference in the compliance to S-1 between Asian and Caucasian populations. ? 2010 Springer-Verlag. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959581533&doi=10.1007%2fs00280-010-1416-8&partnerID=40&md5=7635db9d01321d72647b5ceff2d76fec https://scholars.lib.ntu.edu.tw/handle/123456789/543511 |
ISSN: | 0344-5704 | DOI: | 10.1007/s00280-010-1416-8 | SDG/關鍵字: | gimeracil plus oteracil potassium plus tegafur; abdominal distension; adult; advanced cancer; aged; anemia; anorexia; article; asthenia; clinical article; diarrhea; drug dose reduction; drug efficacy; drug fatality; drug response; drug safety; female; hand foot syndrome; histopathology; human; kidney function; leukopenia; liver toxicity; male; multiple cycle treatment; nausea; nephrotoxicity; neutropenia; overall survival; phase 2 clinical trial; priority journal; progression free survival; single drug dose; stomach cancer; stomatitis; Taiwan; thrombocytopenia; vomiting; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian Continental Ancestry Group; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Taiwan; Tegafur |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。